Recent developments in the virology and antiviral research of severe acute respiratory syndrome coronavirus.
This article summarizes the significant developments and new discoveries in both the virology and antiviral research associated with the severe acute respiratory syndrome coronavirus (SARS CoV) that were reported in 2005 and 2006. Areas reviewed include genomic studies and the identification of bat-SARS CoV, spike protein and host cell entry, nucleocapsid protein, accessory proteins, non-structural proteins of the replicase complex, viral proteases and their inhibitors, and clinical treatment of SARS with ribavirin.
Yeung
Kap-Sun
KS
Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, P.O.Box 5100, Wallingford, Connecticut 06492, USA. kapsun.yeung@bms.com
Meanwell
Nicholas A
NA
D000818:Animals; D000914:Antibodies, Viral / Q000187:drug effects; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002685:Chiroptera; D004195:Disease Models, Animal; D016679:Genome, Viral; D006801:Humans; D008562:Membrane Glycoproteins / Q000378:metabolism; D010447:Peptide Hydrolases / Q000378:metabolism; D034741:RNA, Small Interfering; D012254:Ribavirin / Q000627:therapeutic use; D045473:Severe acute respiratory syndrome-related coronavirus / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D045169:Severe Acute Respiratory Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics / Q000821:virology; D064370:Spike Glycoprotein, Coronavirus; D014759:Viral Envelope Proteins / Q000378:metabolism; D014764:Viral Proteins / Q000378:metabolism; D014765:Viral Vaccines / Q000627:therapeutic use
D000914:Antibodies, Viral; D000998:Antiviral Agents; D008562:Membrane Glycoproteins; D034741:RNA, Small Interfering; D064370:Spike Glycoprotein, Coronavirus; D014759:Viral Envelope Proteins; D014764:Viral Proteins; D014765:Viral Vaccines; D012254:Ribavirin; D010447:Peptide Hydrolases